Transcription of HIGHLIGHTS OF PRESCRIBING INFORMATION A single …
{{id}} {{{paragraph}}}
Example: bachelor of science
HIGHLIGHTS OF PRESCRIBING INFORMATION A single …
HIGHLIGHTS OF PRESCRIBING INFORMATIONT hese HIGHLIGHTS do not include all the INFORMATION needed to use ZERBAXA safely and effectively. See full PRESCRIBING INFORMATION for (ceftolozane and tazobactam) for injection,for intravenous useInitial Approval: 2014----------------------------INDICATI ONS AND USAGE----------------------------ZERBAXA (ceftolozane and tazobactam) is a combination product consisting of a cephalosporin-class antibacterial drug and a beta-lactamase inhibitor indicated for the treatment of the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections, used in combination with metronidazole( ) Complicated Urinary Tract Infections, including Pyelonephritis( )To reduce the development of drug-resistant bacteriaand maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
Infections (cUTI), Including Pyelonephritis 1.5g 7days Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) 3g 8-14days * Used in conjunction with metronidazole 500mg intravenously every 8hours Recommended Dosage of ZERBAXA in Adult Patients with CrCl 50mL/minor less (2.2)
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: